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A rational approach for generating cardiac
troponin I selective Spiegelmers†
Zsuzsanna Szeitner,a Gergely Lautner,b Szilvia K. Nagy,a Ro´bert E. Gyurcsa´nyi*b and
Tama´s Me´sza´ros*ac
We report the first protein selective Spiegelmers of diagnostic
relevance by rational identification of a target epitope and reverse
screening of Spiegelmer candidates following the selection proce-
dure. Application of the presented approach resulted in isolation of
cardiac troponin I selective Spiegelmers with low nanomolar dis-
sociation constant and functionality in serum.
Aptamers are oligonucleotide ligands that bind to their targets with
high selectivity and aﬃnity, rivaling the characteristics of antibody–
antigen interactions.1 Furthermore, due to their in vitro selection
procedure, entirely controlled chemical synthesis, and small size,
aptamers are superior to antibodies in many terms, and thus have
great potential for therapeutic and diagnostic applications.2,3
Despite the large number of innovative detection schemes, a break-
through in practical and commercial exploitation of aptamers is still
awaited. Hitherto, only mycotoxin and vascular endothelial growth
factor selective aptamers have been marketed for food analysis and
treatment of age-related macular degeneration, respectively.4,5 The
development of the latter presents one of the main limitations for
their application as therapeutic agents and diagnostic receptors.
Namely, oligonucleotides are susceptible to the ubiquitously present
nucleases, and thus rapidly degrade in the body fluids.6 Therefore,
techniques have emerged for generation of aptamers built from
modified nucleotides with enhanced nuclease resistance. Although
different unnatural nucleotides have been successfully applied to
increase the half-life of aptamers, none of them seems to be entirely
nuclease resistant.7 To date, the only exceptions demonstrating
seemingly complete resistance to enzymatic degradation are those
composed of L-ribose or L-20-deoxyribose units, i.e., Spiegelmers.8
These oligonucleotides are enantiomers of natural RNA and DNA
molecules, possess the chemical properties of aptamers, but are
unsusceptible to nuclease digestion. Generation of Spiegelmers is a
more elaborate procedure than selection of aptamers and requires
the equivalent mirror image of protein targets. Due to the limita-
tions of peptide synthesis, production of the D-enantiomer of
proteins is practically not feasible. Consequently, most of the
reported Spiegelmers have been selected for cytokines and peptide
hormones.9,10 Notwithstanding, considering that aptamers and
Spiegelmers do not recognize their full protein targets but interact
with them via definite amino acid motifs, protein selective Spiegel-
mers can be isolated without application of proteins.11 This
approach follows the rationality of antibody generation by using
peptides of identified epitopes of protein molecules. Feasibility of
this method has been demonstrated by isolation of Spiegelmers
for a bacterial enterotoxin using a 25-mer D-amino acid peptide.12
We developed this method further to produce Spiegelmers for
cardiac troponin I (cTnI), one of the gold standard biomarkers of
acute coronary syndrome (Fig. 1).
Although cTnI is released into the circulation upon myocardial
injury, its detection is hampered by multiple factors among which
are proteolytic degradation, phosphorylation, complexing with other
molecules and cTnI-specific autoantibodies circulating in the blood
of patients,13 as well as cross-reactivity of c-TnI receptors with
skeletal muscle specific troponins (sTnIs).14 To alleviate these
diﬃculties of troponin measurement, we carefully determined a
9-mer peptide hallmark sequence of cTnI. In comparison to sTnIs,
Fig. 1 Schematics of the cTnI selective Spiegelmer generating protocol.
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cTnI possesses an N-terminal extension; hence, assigning an amino
acid sequence from this region is expected to ensure the troponin I
discriminating capacity of selected Spiegelmers.15 Although the
N-terminal domain is an optimal choice in terms of selectivity of
troponin I isoforms, both terminals of cTnI are extremely suscep-
tible to proteolytic degradation; therefore, determination of the cTnI
concentration using receptors that bind to the N-terminal of the
protein could result in misleading data.16 Further important factors
influencing accurate detection of cTnI are its interaction with
troponin C and phosphorylation by protein kinase A.17 Considering
these constraints of reliable troponin detection, we chose the epitope
corresponding to positions 28–36 of cTnI. The D-enantiomer peptide
of the assigned amino acid sequence was synthesized (D-cTnI
peptide) and N-terminally extended using a cysteine to covalently
link onto reactive bromoacetyl paramagnetic particles. Prior to
selection of specific aptamers, the single-stranded DNA library of
1014 variants was challenged with unmodified paramagnetic beads
to remove the nonspecifically interacting ssDNAs and obtain the
initial selection library. The D-cTnI peptide specific oligonucleotides
were isolated basically according to the previously described SELEX
procedure by using the peptide-coated paramagnetic beads.18 The
selection cycle was repeated nine times by gradually decreasing the
peptide-coated particle concentration and incubation time com-
bined with increased stringency of washing to enhance the affinity
of selected ssDNAs (see ESI†). Following the last selection step, the
PCR products were inserted into a cloning vector, transfected into
competent cells, and the sequence of 85 inserts was determined by
Sanger sequencing. Analysis of sequencing results indicated a
successful selection by enrichment of the oligonucleotide library.
Out of cloned inserts, 32 had the same sequence, 6 appeared twice,
and the rest represented orphan sequences (Table S1, ESI†).
According to the theory of SELEX, the selection procedure results
in enrichment of those aptamers that bind their target molecules
with the highest aﬃnity. However, it has also been reported that the
selection could be distorted by intrinsic diﬀerences in the amplifica-
tion eﬃciency of nucleic acid templates. Therefore, the most
abundant oligonucleotides of SELEX do not necessarily represent
the highest aﬃnity aptamers.19 Consequently, in order to designate
the most promising aptamers, the isolated oligonucleotides have to
be evaluated individually in terms of their target-binding properties.
To avoid the synthesis of each Spiegelmer candidate, we intro-
duced a prescreening step with a reverse approach to identify the
most promising Spiegelmers, i.e., to characterize the interaction
of isolated D-oligonucleotides and D-cTnI peptide ligands by
using surface plasmon resonance imaging (SPRi-HORIBA
Jobin Yvon). Moreover, to evade the time-consuming and
costly chemical synthesis of oligonucleotides, the evaluated
D-oligonucleotides were produced by PCR using biotinylated
forward and non-modified reverse primers of the selection
library. The obtained fragments of the representative amplifica-
tion reactions were microspotted using a solid contact pin onto
ExtrAvidin coated SPR chips and directly converted into ssDNA
by alkali denaturation for interaction analysis. Diﬀerent concen-
tration of D-cTnI peptide in selection buﬀer was flown over the
sensor slides to estimate the aﬃnity between selected oligo-
nucleotides and D-cTnI peptides (Fig. 2).
According to these results, all studied oligonucleotides can
bind the selected peptide ligand. Of note, the most abundant
oligonucleotide (A4) demonstrated the second smallest aﬃnity
for the D-cTnI peptide aﬃrming the previous finding that the
most frequently represented sequence is not necessarily the
best aptamer candidate.
To investigate whether the binding properties observed during
prescreening of selected D-oligonucleotides using the mirrored cTnI
epitope peptide are indicative of the Spiegelmer–protein binding,
both the most promising (B10) and the most abundant (A4)
sequences were synthesized from L-nucleotides with 50 terminal
thiol labelling. Next, the thiolated Spiegelmers were spotted onto
bare gold sensor slides to characterize their cTnI protein binding
kinetics by SPRi. The Spiegelmer spotted chips were blocked with
(11-mercaptoundecyl)tetra(ethylene glycol) (HS-TEG),20 then incu-
bated with various concentrations of the cTnI protein in selection
buffer (Fig. 3).
The equilibrium dissociation constants of both Spiegelmers and
the troponin protein were in the low nanomolar range (KD = 3.5 nM
for B10 and KD = 10.7 nM for A4) and in agreement with the results
of the D-DNA strand prescreening, the Spiegelmer equivalent of the
most abundant oligonucleotide (A4) possessed a lower aﬃnity
towards the cTnI protein. Thus, the obtained data confirmed the
results of the oligonucleotide screening experiment implying perti-
nence of the proposed reverse approach for identification of the
most promising Spiegelmer candidates.
Having demonstrated the high cTnI aﬃnity of selected Spiegel-
mers, we embarked on evaluating their selectivity. cTnI is a positively
charged protein under physiological conditions (pI 10.31); thus, it
could interact with the inherently negatively charged Spiegelmers by
formation of non-selective, electrostatic interactions. To investigate
this possibility, we measured the interaction of Spiegelmers with
lysozyme (pI 11.35) – a protein notorious for non-specific binding –21
using the Spiegelmer spotted sensor slides (Fig. 4). No increase in the
SPR signal was detected indicating that the electrostatic intermolec-
ular forces between the Spiegelmer and cTnI are disrupted at the
Fig. 2 Binding of the D-cTnI peptide at diﬀerent concentrations to
selected D-oligonucleotides as determined by SPRi. The selected, biotiny-
lated oligonucleotides (A4, B10, C11 and D12) were immobilized by
microspotting 10 mM solutions of each onto an ExtrAvidin modified SPRi
sensor chip. * (Po 0.05) and ** (Po 0.01) denote a significant diﬀerence
in reflectivity changes between tested oligonucleotides and the control.
Error bars show the standard error, n = 3.
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physiological ionic strength. The raised cTnI level in blood is a very
specific indicator of cardiac muscle damage; however, false-positive
values can be measured if the applied diagnostic receptor cross
reacts with the closely homologous skeletal muscle troponin I (sTnI)
isoforms. Although our target peptide of the selection procedure is
specific for cTnI, we scrutinized the troponin I selectivity of Spiegel-
mers. To this end, the modified SPR sensor chips were challenged
with purified sTnI. The measurements again revealed lack of
interaction indicating that the analyzed Spiegelmers can discrimi-
nate the troponin I isoforms (Fig. 4).
Following cardiac cell death, the majority of cTnI is released into
the circulation as a part of the ternary complex (cTnI–cTnT–TnC);
therefore, the monomer and also the complex forming cTnI have to
be detected to obtain diagnostically valuable data.16 To evaluate the
cTnI complex perceiving capability of Spiegelmers, SPRi interaction
analysis of Spiegelmer modified sensor chips with the commercial
cTnI–cTnT–TnC protein complex was performed. The measure-
ments showed obvious interactions with both Spiegelmers, and
the SPR signals were higher than those measured with the mono-
mer cTnI, which is in accordance with the larger molecular weight
of the troponin complex (Fig. 3). These results suggest that the
Spiegelmer probes detect both free and complex cTnI forms.
As a proof of their potential diagnostic receptor application, the
Spiegelmers were tested for the selective recognition of cTnI in
human blood serum. To this end, ten times diluted, troponin I free
human serum was spiked with various amounts of cTnI to measure
the cardiac marker protein concentration dependent alterations of
the SPR signal. The results of the analysis showed a cTnI concen-
tration dependent signal increase for both Spiegelmers, and in
concert with the previous experiments, the most promising Spie-
gelmer (B10) demonstrated higher sensitivity for cardiac troponin I
detection (Fig. 5).
Finally, to assess if the selected Spiegelmers meet the stability
requirement of an ideal diagnostic receptor, the Spiegelmer spotted
chip was desiccated and stored at 4 1C for six months, then
challenged with cTnI. The SPRi measurements revealed no loss of
sensitivity of the Spiegelmer modified sensor slides. Furthermore,
the chips withstoodmultiple harsh regeneration steps using 20mM
NaOH, as shown by the unchanged SPR responses of subsequent
cTnI measurements (Fig. S1, ESI†).
The in serum stability and analytical performance of the
selected Spiegelmers imply that they have the potential to be used
as cTnI specific receptors in cardiovascular diagnostic assays.
Label-free SPR measurements are appropriate for kinetic character-
ization of aﬃnity interactions, but they are not sensitive enough
for analytical cTnI assays in the diagnostically relevant range
(0.04–100 ng mL1). However, what is important from the receptor
development point of view is the KD of the Spiegelmer–cTnI
complex, as the smaller this value the lower the expected LOD is.
A thorough analysis of National Institute of Standards and Tech-
nology has revealed that the monoclonal antibodies of high
sensitivity cTnI diagnostic kits possess KD values in the 74 nM–
2.6 mM range, which are at least an order higher than that of our
Spiegelmers.22 Therefore, it is expected that implementing a label-
based amplification or a more sensitive detection technique, that is
currently in development in our laboratories, the relevant dia-
gnostic range of cTnI will be achievable. The superiority of the
cTnI sensing capabilities of the Spiegelmer-modified chips is also
highlighted by the fact that selective determination was achieved at
low serum dilutions while conventional ELISA methods may need
higher dilutions and a set of monoclonal antibodies to avoidmatrix
effects and infer selectivity.23
Fig. 3 SPR binding curves of the cTnI protein at various concentrations to
surface immobilized A4 (top) and B10 (bottom) Spiegelmers. cTnI was
injected in selection buﬀer at 125, 250, 500 and 1000 ng mL1 concen-
trations (bottom-up).
Fig. 4 Selectivity of B10 (a) and A4 (b) Spiegelmers expressed through the
amount of protein bound to the Spiegelmermodified surfaces upon interaction
with 1 mgmL1 solutions of cTnI, the troponin complex (cTnI–cTnT–TnC), sTnI
and lysozyme was determined by SPRi. Error bars show the standard error,
n = 3. * (P o 0.05), ** (Po 0.01) and *** (Po 0.0005).
ChemComm Communication
Pu
bl
ish
ed
 o
n 
06
 M
ay
 2
01
4.
 D
ow
nl
oa
de
d 
by
 B
ud
ap
es
t U
ni
ve
rs
ity
 o
f T
ec
hn
ol
og
y 
an
d 
Ec
on
om
ic
s o
n 
25
/0
7/
20
14
 1
3:
22
:5
1.
 
View Article Online
6804 | Chem. Commun., 2014, 50, 6801--6804 This journal is©The Royal Society of Chemistry 2014
In summary, here we showed an approach indicating that
protein selective Spiegelmers can be eﬀectively produced by a
rational identification of relevant protein epitopes combined with
SPRi screening of isolated Spiegelmer candidates. The selection
protocol resulted in isolation of a cardiovascular marker protein
discriminatory Spiegelmers, which could be potentially applied in
diagnostic assay development, as demonstrated by blood serum
measurements and lack of cross-reactivity to sTnI.
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